A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Recruiting now

Conditions studied: Gastroenteropancreatic Neuroendocrine Tumor

In brief

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.

Key facts

Study ID

NCT07635316

Run by

Novartis Pharmaceuticals

People needed

4023

Starts

2026-06-12

Expected to finish

2027-02-25

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date.
• Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs [SSAs], targeted therapy, peptide receptor radionuclide therapy [PRRT], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date.
• Patients ≥18 years of age on the index date
• Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:
• ≥1 medical and pharmacy claim >12 months prior to the index date; AND
• ≥1 medical and pharmacy claim within the first 6 months of the 12-month period prior to the index date; AND
• ≥1 medical and pharmacy claim during the last 6 months of the 12-month period prior to the index date; AND
• Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:
• ≥ 1 pharmacy dispensing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date
• ≥ 1 provider prescribing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date

You may not qualify if…

• Patients with evidence of GEP-NET prior to the diagnosis date within the study period
• Patients with evidence of GEP-NET treatment prior to the index date within the study period
• Patients with missing or invalid age or sex
• Patients with other primary malignancies during the 12-month pre-index period
• Patients with invalid death date (i.e., death date ≤ index date)

Where it is running

• Novartis — East Hanover, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.